Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome

Clinical Immunology

Volumn 141, Issue 1, 2011, Pages 103-110

  Chandra, Abhishek ^a   Latov, Norman ^a   Wormser, Gary P ^b   Marques, Adriana R ^c   Alaedini, Armin ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibody; Chronic Lyme disease; Epitope mapping; Lyme disease; Post Lyme disease syndrome; VlsE

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VLSE PROTEIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BORRELIA BURGDORFERI; CONTROLLED STUDY; CRYSTAL STRUCTURE; EPITOPE MAPPING; FATIGUE; FEMALE; HUMAN; LYME DISEASE; MALE; MICROARRAY ANALYSIS; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORRELIA BURGDORFERI; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; LIPOPROTEINS; LYME NEUROBORRELIOSIS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN ARRAY ANALYSIS; SYNDROME;

EID: 80053132733     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.06.005     Document Type: Article

References (28)

1. Marques A.R. Lyme disease: a review. Curr. Allergy Asthma Rep. 2010, 10:13-20.
2. Steere A.C., Coburn J., Glickstein L. The emergence of Lyme disease. J. Clin. Invest. 2004, 113:1093-1101.
3. Stanek G., Strle F. Lyme borreliosis. Lancet 2003, 362:1639-1647.
4. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 43:1089-1134.
5. Bratton R.L., Whiteside J.W., Hovan M.J., Engle R.L., Edwards F.D. Diagnosis and treatment of Lyme disease. Mayo Clin. Proc. 2008, 83:566-571.
6. Marques A. Chronic Lyme disease: a review. Infect. Dis. Clin. North Am. 2008, 22:341-360.
7. Feder H.M., Johnson B.J., O'Connell S., et al. A critical appraisal of "chronic Lyme disease". N. Engl. J. Med. 2007, 357:1422-1430.
8. Baker P.J. Perspectives on "chronic Lyme disease". Am. J. Med. 2008, 121:562-564.
9. Klempner M.S., Hu L.T., Evans J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 2001, 345:85-92.
10. Krupp L.B., Hyman L.G., Grimson R., et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003, 60:1923-1930.
11. Fallon B.A., Keilp J.G., Corbera K.M., et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008, 70:992-1003.
12. Zhang J.R., Hardham J.M., Barbour A.G., Norris S.J. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997, 89:275-285.
13. Philipp M.T., Bowers L.C., Fawcett P.T., et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J. Infect. Dis. 2001, 184:870-878.
14. Fleming R.V., Marques A.R., Klempner M.S., et al. Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:615-618.
15. Liang F.T., Steere A.C., Marques A.R., Johnson B.J., Miller J.N., Philipp M.T. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J. Clin. Microbiol. 1999, 37:3990-3996.
16. Liang F.T., Alvarez A.L., Gu Y., Nowling J.M., Ramamoorthy R., Philipp M.T. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J. Immunol. 1999, 163:5566-5573.
17. Embers M.E., Jacobs M.B., Johnson B.J., Philipp M.T. Dominant epitopes of the C6 diagnostic peptide of Borrelia burgdorferi are largely inaccessible to antibody on the parent VlsE molecule. Clin. Vaccine Immunol. 2007, 14:931-936.
18. Liang F.T., Bowers L.C., Philipp M.T. C-terminal invariable domain of VlsE is immunodominant but its antigenicity is scarcely conserved among strains of Lyme disease spirochetes. Infect. Immun. 2001, 69:3224-3231.
19. Chandra A., Wormser G.P., Klempner M.S., et al. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav. Immun. 2010, 6:1018-1024.
20. Chandra A., Wormser G.P., Marques A.R., Latov N., Alaedini A. Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome. Clin. Vaccine Immunol. 2011, 18:767-771.
21. Aguero-Rosenfeld M.E., Wang G., Schwartz I., Wormser G.P. Diagnosis of lyme borreliosis. Clin. Microbiol. Rev. 2005, 18:484-509.
22. CDC Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb. Mortal. Wkly Rep. 1995, 44:590-591.
23. Wenschuh H., Volkmer-Engert R., Schmidt M., Schulz M., Schneider-Mergener J., Reineke U. Coherent membrane supports for parallel microsynthesis and screening of bioactive peptides. Biopolymers 2000, 55:188-206.
24. Eicken C., Sharma V., Klabunde T., et al. Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi. J. Biol. Chem. 2002, 277:21691-21696.
25. Liang F.T., Philipp M.T. Epitope mapping of the immunodominant invariable region of Borrelia burgdorferi VlsE in three host species. Infect. Immun. 2000, 68:2349-2352.
26. van Meerten T., Rozemuller H., Hol S., et al. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica 2010, 95:2063-2071.
27. Zwick M.B., Labrijn A.F., Wang M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.
28. Vanlandschoot P., Beirnaert E., Barrere B., et al. An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. J. Gen. Virol. 1998, 79(Pt 7):1781-1791.